Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynecologic cancer

Oncology

Volumn 64, Issue 1, 2003, Pages 46-53

  Sagae, Satoru ^a   Ishioka, Shin Ichi ^a   Fukunaka, Noriyoshi ^a   Terasawa, Katsuhiko ^a   Kobayashi, Kanji ^a   Sugimura, Masaki ^a   Nishioka, Yoshihiro ^a   Kudo, Ryuichi ^a   Minami, Masaru ^b  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Chemotherapy; Delayed emesis; Droperidol; Granisetron; Gynecologic cancer; Methylprednisolone

Indexed keywords

CISPLATIN; DROPERIDOL; GRANISETRON; METHYLPREDNISOLONE;

ACUTE DISEASE; ADULT; ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; TIME; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; CROSS-OVER STUDIES; DROPERIDOL; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; METHYLPREDNISOLONE; MIDDLE AGED; NAUSEA; OVARIAN NEOPLASMS; PREMEDICATION; UTERINE NEOPLASMS; VOMITING;

EID: 0037213990     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066522     Document Type: Article

References (24)

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al: On the receiving end - Patient perception of the side effects of cancer chemotherapy. Eur J Cancer 1983;19:203-208.
2. Andrews PLR, Davis CJ: The mechanism of emesis induced by anti-cancer therapies; in Andrews PLR, Sanger GJ (eds): Emesis in Anticancer Therapy: Mechanisms and Treatment. London, Chapman & Hall, 1993, pp 113-162.
3. Minami M, Endo T, Nemoto M, Hanaue N, Hirafuji M, Monma Y, Yajima T, Yoshioka M, Saito H: How do toxic emetic stimuli cause serotonin release in the gut and the brain; in Reynolds DJM, Andrews PLR, Davis CJ (eds): Serotonin and the Scientific Basis of Antiemetic Therapy. Oxford Clinical Communications, Oxford, 1995, pp 68-76.
4. Grunberg SM, Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med 1993; 329:1790-1796.
5. 3 receptor antagonists: Differences and similarities. Eur J Cancer 1997;33:1364-1370.
6. The Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995;6:805-810.
7. The Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
8. Carmichael J, Bessel EM, Harris AL, Hutcheon AW, Dawes PJ, Daniels S: Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer 1994;70:1161-1164.
9. Fukunaka N, Sagae S, Kudo R, Endo T, Hirafuji M, Minami M: Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. Gen Pharmacol 1998;31:775-781.
10. Sridhar KS, Donnelly E: Combination antiemetics for cisplatin chemotherapy. Cancer 1988;61:1508-1517.
11. Sagae S, Fukunaka N, Terasawa K, Ishioka S, Kobayashi K, Saito T, Kudo R: Randomized cross-over comparative studies of combinations of granisetron, methylprednisolone and droperidol as antiemetic prophylaxis in CDDP-based chemotherapy for gynecologic cancer. Proc Am Soc Clin Oncol 1999;18:606a.
12. Kirchner V, Aapro M, Terrey J-P, Alberto P: A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy. Eur J Cancer 1997;33:1605-1610.
13. The Italian Group for Antiemetic Research: Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients ? Ann Oncol 1997;8:561-567.
14. Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, et al: Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis - JCOG study 9413. Br J Cancer 1997;76:90-92.
15. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al: Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:1174-1178.
16. Roila F, Ballatori E: The efficacy and cost-effectiveness of various antiemetic regimens. Curr Opin Oncol 1998;10:310-315.
17. Aapro MS, Alberts DS: Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med 1981;305:520-526.
18. Jacobs AJ, Deppe G, Cohen CJ: A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cis-platinum. Gynecol Oncol 1980;10:55-57.
19. Italian Group for Antiemetic Research: Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Support Care Cancer 1994;2:167-170.
20. Grossman B, Lessin LS, Cohen P: Droperidol prevents nausea and vomiting from cis-platinum. N Engl J Med 1979;301:46.
21. Gumbart CH, Sorensen SH, Bickers JN: A comparison of metoclopramide vs. droperidol/phenobarbital for emesis induced by chemotherapy. Am J Med Sci 1987;293:90-93.
22. Singh L, Field MJ, Hughes J, Kuo BS, Suman-Chauhan N, Tuladhar BR, et al: The tachykinin NK1 receptor antagonist PD154075 blocks cisplatin-induced delayed emesis in the ferret. Eur J Pharmacol 1997;321:209-216.
23. Minami M, Endo T, Kikuchi K, Ihira E, Hirafuji M, Hamaue N, Monma Y, Sakurada T, Tan-no K, Kisara K: Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret. Eur J Pharmacol 1998;363:49-55.
24. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ: Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997;89:817-818.